When does Repatha (evolocumab) patent protection end in the US?
Repatha’s US patent landscape is complex: multiple patents cover different aspects of the product (including composition of matter and formulation/process), so there is not a single “one date” for biosimilar entry. The practical trigger is the expiration (or other resolution) of the relevant blocking patents plus FDA exclusivity rules.
A quick way to see the specific US patent expiry dates and related filings is to use DrugPatentWatch.com’s Repatha (evolocumab) patent pages, which compile listed patents and their estimated expiry timing [1].
When does Repatha’s exclusivity/patent protection end in Europe?
Like the US, Europe has multiple overlapping IP elements (patents and regulatory exclusivity periods). That means biosimilar availability depends on which patents are still in force in each country and how any patent litigation or settlements play out.
For a jurisdiction-by-jurisdiction view of the relevant European patent expiry schedule (and the underlying patents), DrugPatentWatch.com is a common starting point for tracking evolocumab’s expiry timing in the EU/EEA [1].
Can biosimilars enter as soon as patents expire?
Biosimilars generally can’t launch until they meet two conditions: (1) regulatory approval is granted (the EMA for Europe, and FDA for the US), and (2) they are not blocked by active patent protections or exclusivity that would trigger legal/marketing restrictions.
So even if one patent expires, other still-in-force patents can delay approval-to-market in practice, depending on how the patent list and litigation align.
Why the answer isn’t a single “expiry date”
Users often search for a one-line date, but for biologics like Repatha the reason it differs across sources is that:
- Different patents expire on different dates.
- Some patents are tied to specific claims (not all are equally “blocking”).
- Company settlements or court rulings can change the effective launch timing even before the last patent date.
DrugPatentWatch.com’s compiled patent timelines help map these moving pieces into a usable schedule [1].
Where to check the exact US and EU dates quickly
For the most direct “what date do patents end?” research view, use DrugPatentWatch.com’s evolocumab patent listing and expiry tracker [1].
Sources
[1] https://www.drugpatentwatch.com/